Nordic Life Science
Pharma
Latest Pharma News
The money will be used to develop a computer program that can predict how the immune system will react to different substances, reports the company. Today, Immunitrack is offering contracted
The US Food & Drug Administration has granted Fast Track designation to Betalutin (177Lu-lilotomab satetraxetan) for the treatment of patients with relapsed or refractory follicular lymphoma (FL) after at least
The European Commission has granted marketing authorisation for Tagrisso (osimertinib) as monotherapy for the 1st-line treatment of adult patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth
The company starts the clinical development of a potential new treatment of schizophrenia and Alzheimer’s disease and divests two research programs to biotech company MindImmune Therapeutics. A phase I-study in
The Danish pharma company has announced an increased commitment to stem cell-based therapies, something made possible through a collaborations with the University of California San Francisco (UCSF) in which a first
AstraZeneca has submitted a supplemental new drug application (sNDA) to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for the use of Forxiga (dapagliflozin), a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, as an
Clinical trials
Follicum announces that all patients in the Phase IIa clinical trial with FOL-005 for stimulating hair growth have been recruited.
H. Lundbeck A/S and Takeda Pharmaceutical announce positive results from their pivotal study with vortioxetine in adults with Major Depressive
Lundbeck and Otsuka Pharmaceutical announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency
The company has anounced results from PIONEER 2, the second phase 3a trial with oral semaglutide for treatment of adults
The two pharma giants reports data which showed clinical improvement in median radiologic progression-free survival (rPFS) with Lynparza (olaparib) in
The Phase 2b trial with Betalutin (177Lu-satetraxetan-lilotomab) in third-line (3L) follicular lymphoma (FL) patients has been approved by the Regional
The trial, the second of two pivotal Phase III trials for Fasenra (benralizumab) in patients with moderate to very severe chronic obstructive
All subjects have been enrolled and dosed in the second and pivotal Phase 3 trial to confirm the clinical efficacy
The company has received feedback from the Regional Committees for Medical and Health Research Ethics (REK) in Norway with regard
Following a planned review, the Data Monitoring Committee (DMC) has recommended that the Phase Ib/II study (CALLISTO/LUC2001) of daratumumab in
The results from the Phase III study of Arzerra (ofatumumab) plus bendamustine did not meet the primary endpoint of improved
AstraZeneca and MedImmune has announced positive overall survival (OS) results for the Phase III PACIFIC trial, a randomised, double-blinded, placebo-controlled,
BioInvent International has received authorization to proceed from the Swedish Medical Product Agency for a new clinical trial that will
The company starts the clinical development of a potential new treatment of schizophrenia and Alzheimer’s disease and divests two research
The company announces results from its phase I/II trial of ONCOS-102 in mesothelioma, in combination with standard of care chemotherapy,
AstraZeneca and MedImmune announce results from their Phase III ARCTIC trial in patients with locally-advanced or metastatic non-small cell lung
Pharma articles
Immunotherapy is the 2016 Clinical Cancer Advance of the Year and a promising new strategy for treating cancer. But how far have we come? The American Society of Clinical Oncology
The high cost and uncertain outcomes of developing new drugs has taken a toll on research over the past several years. Few companies can take the hit of investing hundreds
Liquid biopsies, sequencing and upgraded software tools are among some of the recent and ongoing trends in cancer diagnostics. Developments in the diagnostic sector have vastly improved the ability to
The rapid development within nanotechnology drug delivery is creating new possibilities to treat common diseases and improving pharmaceuticals. Safety aspects and competitionwith established treatments are however some of the obstacles
Hans Lennernäs, professor in biopharmaceutics at Uppsala University, has extensive experience in developing drug delivery methods. NLS asked him about his research and ongoing activities in the field. He spoke
Much effort is being made to develop new medicines for diabetes and recent findings indicate the potential for new and improved pharmaceuticals. Diabetes is one of the largest global diseases
Profiles in Pharma
Ironically, there is less serendipity in the success Saeid Esmaeilzadeh and Ashkan Pouya have achieved as business-makers than there is
Bahija Jallal’s curiosity and passion for science have been strong driving forces throughout her entire career, as has her belief
After ten years of diabetes research and development at Novo Nordisk, Dorte X. Gram took her findings and work further
Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer at Novo Nordisk, talks about the Danish pharma giant’s drug-development
Sirpa Jalkanen is a professor in the Academy of Finland, board member of Orion, and cofounder with her husband, Markku
Academia and business don’t always mix, but Agnete B. Fredriksen of Norway has found the formula. While doing research for
Logistics
With a deadline looming to meet a new EU Falsification Medicines Directive (FMD) by 2019, there is no shortage of challenges for packaging experts. Besides satisfying EU requirements, drug manufacturers
Packaging is an often overlooked element of the life science supply chain but the industry needs to step up quality and foster innovation in order to keep up with developments